IOVA stock news today

Pomerantz LLP investigates Iovance Biotherapeutics over potential securities claims

Pomerantz LLP is looking into possible securities claims involving Iovance Biotherapeutics. The investigation concerns potential legal issues tied to the company's securities.

Citizens keeps Iovance Biotherapeutics at Market Outperform, lifts price target

Citizens reiterated its Market Outperform rating on Iovance Biotherapeutics and increased its price target on the shares.

Barclays keeps Overweight rating on Iovance Biotherapeutics, lifts target to $19

Barclays stayed positive on Iovance Biotherapeutics and moved its price target up to $19. The change reflects the analyst's updated view on the stock.

Citizens keeps Market Outperform on Iovance Biotherapeutics, lifts target to $12

Citizens restated its Market Outperform rating on Iovance Biotherapeutics and increased its price target to $12. The update reflects the firm's view on the biotech company's shares.

Iovance Biotherapeutics holds Q3 2026 earnings call

Iovance Biotherapeutics held its earnings call for the third quarter of 2026. The call covers the company's quarterly results.

Iovance Biotherapeutics Posts Q3 2026 Financials

The company shared its financial figures for the three months ending in 2026's third quarter. No specific numbers were included in the announcement.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Iovance Biotherapeutics posts smaller quarterly loss as revenue tops estimates

The biotech company reported a third-quarter loss of $0.05 per share, narrower than the $0.09 loss analysts expected. Revenue reached $121.469 million, beating the $115.982 million forecast.

Iovance Biotherapeutics restates FY2026 sales outlook of $410M to $420M

Iovance Biotherapeutics reaffirmed its full-year 2026 revenue forecast of $410 million to $420 million. That range brackets the $416.263 million consensus estimate.

UBS keeps Neutral rating on Iovance Biotherapeutics, lifts price target to $8

UBS stayed Neutral on Iovance Biotherapeutics while raising its price target to $8. The change reflects the analyst's updated view of the stock.

UBS keeps Neutral rating on Iovance Biotherapeutics, lifts target to $8

UBS stayed Neutral on Iovance Biotherapeutics while raising its price target to $8. The update reflects the analyst's current view on the stock.

Iovance Biotherapeutics shares new IOV-LUN-202 data and a precision TIL plan for mNSCLC

The company released fresh findings from its IOV-LUN-202 study and outlined a precision TIL approach aimed at metastatic non-small cell lung cancer.

Iovance Biotherapeutics schedules webcast on favorable lung cancer trial results

Iovance Biotherapeutics plans a webcast to share favorable findings for its tumor-infiltrating lymphocyte treatment in advanced non-small cell lung cancer. The results concern this cancer type.

Iovance Biotherapeutics Releases Last Phase 2 Results for Lifileucel Combo in Frontline Advanced Melanoma

The company shared its concluding Phase 2 findings for lifileucel given alongside other therapy in previously untreated advanced melanoma. The readout covers the study's last data for this use.

H.C. Wainwright keeps Buy rating on Iovance Biotherapeutics

H.C. Wainwright reiterated its Buy rating for Iovance Biotherapeutics. The note repeats the firm's positive stance on the biotech company's shares.

Iovance Reports Durable Responses for Lifileucel in Soft Tissue Sarcoma at ESMO 2026

Iovance presented data at ESMO 2026 showing durable responses with its lifileucel TIL cell therapy in patients with advanced soft tissue sarcomas. The results support further study of the treatment in this cancer type.

Iovance Presents Lifileucel Monotherapy Data in Two Sarcoma Types

Iovance Biotherapeutics said its therapy lifileucel, given alone, produced deep and lasting responses in patients with metastatic UPS and DDLPS. The findings were presented at a 2026 medical conference.

Iovance Phase 2 data: lifileucel plus pembrolizumab shows 62.5% ORR in frontline advanced melanoma

Iovance reported that its experimental combination of lifileucel and pembrolizumab produced a 62.5% overall response rate in previously untreated advanced melanoma. Nearly three in ten patients had no detectable disease, and median overall survival was not reached at a follow-up of 50.9 months.

Iovance Biotherapeutics will share fresh trial results at ESMO Congress 2026

The company said it will disclose additional findings from its studies at the ESMO Congress 2026. The data covers its clinical programs.

Barclays keeps Overweight rating on Iovance Biotherapeutics, lifts target to $18

Barclays reiterated its Overweight rating on Iovance Biotherapeutics and increased its price target to $18. The move reflects the firm's updated view on the biotech company.

Baird keeps Neutral rating on Iovance Biotherapeutics, lifts target to $11

Baird reiterated a Neutral rating on Iovance Biotherapeutics while raising its price target to $11. The update reflects the firm's latest view on the biotech company's shares.

Iovance Biotherapeutics holds Q2 2026 earnings conference call

Iovance Biotherapeutics discussed its second-quarter 2026 results during an earnings conference call. A transcript of the call is available.

Wells Fargo keeps Overweight rating on Iovance Biotherapeutics, lifts target to $18

Wells Fargo reiterated an Overweight rating on Iovance Biotherapeutics and increased its price target to $18. The update reflects the firm's latest analyst view on the biotech company.

What is the latest news on IOVA?

Nov 6, 2026: Pomerantz LLP investigates Iovance Biotherapeutics over potential securities claims (Fiscal.ai) · Nov 6, 2026: Citizens keeps Iovance Biotherapeutics at Market Outperform, lifts price target (Fiscal.ai) · Nov 6, 2026: Barclays keeps Overweight rating on Iovance Biotherapeutics, lifts target to $19 (Benzinga)

What has IOVA filed with the SEC recently?

Nov 5, 2026: Iovance Biotherapeutics, Inc. filed a report on a major company event (Form 8-K)